Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Erik Jakobsen"'
Autor:
Neelima Denduluri, Marc Buyse, Robert Šeparović, Bent Ejlertsen, Stephen Chia, Gunter von Minckwitz, Alshad S. Lalani, Michael Gnant, Frankie A. Holmes, John A. Smith, Vernon Harvey, Bo Zhang, Hiroji Iwata, Janine Mansi, Beverly Moy, Sung-Bae Kim, Nicholas J. Robert, Yining Ye, Carlos H. Barrios, Erik Jakobsen, Arlene Chan, Suzette Delaloge, Miguel Martin, Lisa D. Eli, Z Tomasevic, Graydon Harker
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free